This paragraph in the article is the same used in
Post# of 148171
(Total Views: 634)
Posted On: 05/29/2020 10:45:34 AM
This paragraph in the article is the same used in numerous others; wish they would expound further on it:
Don't misunderstand it's great having the publicity through all of these articles in various publications (hope DoctorsLounge has lots of visitors), but they just cut-and-paste an important message without further investigation or information... I'm wondering who or what publication first wrote this (HealthDay?- just left them message so if I hear anything I'll post it); they should have more or follow up on Leronlimab and the study... seems the original source of the info at least for baricitinib came from the Fed,(FDA?) but it's unknown whether that same Fed source spoke of CytoDyn or the info came from the company or elsewhere.
Quote:
Already, combinations of remdesivir and other drugs are being tried, to see if dual-drug treatments might boost outcomes even more. For example, one federally funded clinical trial is combining remdesivir with a potent anti-inflammatory drug called baricitinib, while a trial from biotech firm CytoDyn is pairing it with an antiviral called leronlimab.
Don't misunderstand it's great having the publicity through all of these articles in various publications (hope DoctorsLounge has lots of visitors), but they just cut-and-paste an important message without further investigation or information... I'm wondering who or what publication first wrote this (HealthDay?- just left them message so if I hear anything I'll post it); they should have more or follow up on Leronlimab and the study... seems the original source of the info at least for baricitinib came from the Fed,(FDA?) but it's unknown whether that same Fed source spoke of CytoDyn or the info came from the company or elsewhere.
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼